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Abstract
Introduction Predicting the clinical course of breast cancer is
often difficult because it is a diverse disease comprised of many
biological subtypes. Gene expression profiling by microarray
analysis has identified breast cancer signatures that are
important for prognosis and treatment. In the current article, we
use microarray analysis and a real-time quantitative reverse-
transcription (qRT)-PCR assay to risk-stratify breast cancers
based on biological 'intrinsic' subtypes and proliferation.
Methods Gene sets were selected from microarray data to
assess proliferation and to classify breast cancers into four
different molecular subtypes, designated Luminal, Normal-like,
HER2+/ER-, and Basal-like. One-hundred and twenty-three
breast samples (117 invasive carcinomas, one fibroadenoma
and five normal tissues) and three breast cancer cell lines were
prospectively analyzed using a microarray (Agilent) and a qRT-
PCR assay comprised of 53 genes. Biological subtypes were
assigned from the microarray and qRT-PCR data by hierarchical
clustering. A proliferation signature was used as a single meta-
gene (log2 average of 14 genes) to predict outcome within the
context of estrogen receptor status and biological 'intrinsic'
subtype.
Results We found that the qRT-PCR assay could determine the
intrinsic subtype (93% concordance with microarray-based
assignments) and that the intrinsic subtypes were predictive of
outcome. The proliferation meta-gene provided additional
prognostic information for patients with the Luminal subtype (P
= 0.0012), and for patients with estrogen receptor-positive
tumors (P  = 3.4 × 10-6). High proliferation in the Luminal
subtype conferred a 19-fold relative risk of relapse (confidence
interval = 95%) compared with Luminal tumors with low
proliferation.
Conclusion A real-time qRT-PCR assay can recapitulate
microarray classifications of breast cancer and can risk-stratify
patients using the intrinsic subtype and proliferation. The
proliferation meta-gene offers an objective and quantitative
measurement for grade and adds significant prognostic
information to the biological subtypes.
DWD = distance-weighted discrimination; ER = estrogen receptor; IHC = immunohistochemistry; PCR = polymerase chain reaction; qRT = quanti-
tative reverse-transcription; RFS = relapse-free survival.Breast Cancer Research    Vol 8 No 2    Perreard et al.
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Introduction
Current management of breast cancer is based on anatomic
staging (tumor size/node involvement/metastasis) and mor-
phological features such as the tumor grade [1]. Although ana-
tomic staging and histological grade are important prognostic
factors [2], they often fail to predict the clinical course of the
disease. In order to improve upon the standard of care for
breast cancer, there is a need for new molecular markers and
diagnostic algorithms.
Microarray studies have shown that differences in gene
expression can account for much of the diversity in breast can-
cer and that these profiles have prognostic significance [3-8].
A common method to find similarities (and differences) in the
biology of breast cancer is to hierarchical cluster an 'intrinsic'
gene set [3-5]. By definition, intrinsic genes have a large vari-
ation in expression across tumors from different individuals but
have little variation in expression between biological replicates
from the same individual; intrinsic genes therefore identify dis-
tinct tumor biology that could explain differences in phenotype
(for example, drug response).
Hierarchical clustering of microarray data using an intrinsic
gene set has shown that breast cancers can be classified into
at least four groups: Luminal, Normal-like, HER2+/ER, and
Basal-like [3]. Additional studies using larger numbers of
patients have shown that these subtypes can be identified in
independent data sets, and that the different classes are prog-
nostic [5,6,9].
Breast tumors of the 'Luminal' subtype are estrogen receptor
(ER)-positive and have a similar keratin expression profile to
the epithelial cells lining the lumen of the breast ducts
[4,5,10,11]. Conversely, ER-negative tumors can be divided
into two main subtypes – namely those that overexpress (and
are DNA amplified for) HER2 and GRB7 (HER2+/ER-), and
'Basal-like' tumors that have an expression profile similar to
basal epithelium and express keratin 5, keratin 6B, keratin 14
and keratin 17. The ER-negative tumor subtypes are aggres-
sive and typically more deadly than Luminal tumors; however,
there are subtypes of Luminal tumors that lead to poor out-
comes despite being ER-positive [3,4,6]. For example, Sorlie
and colleagues identified a Luminal B subtype with similar out-
comes to the HER2+/ER- and Basal-like subtypes [4], and
Sotiriou and colleagues showed that there are three different
types of Luminal tumors with different outcomes [6]. The Lumi-
nal tumors with poor outcomes consistently share the his-
topathological feature of being higher grade and the molecular
feature of showing high expression of proliferation genes [4-
6].
Proliferation genes are cell-cycle-regulated genes that have a
variety of functions necessary for cell growth, DNA replication,
and mitosis [12,13]. Despite their diverse functions, prolifera-
tion genes have similar gene expression profiles when ana-
lyzed by hierarchical clustering. Furthermore, studies using
supervised analyses to find genes that predict outcome com-
monly identify proliferation genes. For example, the SAM264
'survival' list stated in Sorlie and colleagues [4], the 231 'prog-
nosis classifier' list of van 't Veer and colleagues [7], and the
485 prognostic genes presented in Sotiriou and colleagues
[6] all contained proliferation genes, suggesting that all of
these studies are probably tracking a similar phenotype.
The main objectives of this study are to compare molecular
subtype classification between microarray analysis and real-
time quantitative reverse-transcription (qRT)-PCR analysis,
and to assess the prognostic significance of a proliferation
meta-gene, both as an independent marker and within the con-
text of the breast cancer subtypes.
Materials and methods
Patient selection
An ethnically diverse cohort of patients was studied using
samples collected from the University of Utah Health Sciences
Center, from the University of North Carolina, from Thomas Jef-
ferson University, from the Maine Medical Center, and from the
University of Chicago. Patients provided written acknowledge-
ment of informed consent in accordance with institutional and
federal guidelines. Samples collected prospectively for micro-
array and qRT-PCR analyses included 117 invasive breast
cancers, one fibroadenoma, five 'normal' samples (from reduc-
tion mammoplasty), and three cell lines. Patients were treated
in accordance with the standard of care dictated by their dis-
ease stage, ER status, and HER2 status. Patient outcome
information was collected for up to 118 months (median 21.5
months). The clinical data for the qRT-PCR samples are pre-
sented in Additional file 2 (Supplemental Table 1). Publicly
available data sets containing 337 samples with long-term fol-
low-up (median 86.7 months) were used to further validate the
prognostic significance of the proliferation meta-gene within
the context of intrinsic subtypes [7,8,14].
Sample preparation and first-strand synthesis for qRT-
PCR
Nucleic acids were extracted from fresh frozen tissue using
the RNeasy Midi Kit (Qiagen Inc., Valencia, CA, USA). The
quality of RNA was assessed using the Agilent 2100 Bioana-
lyzer with the RNA 6000 Nano LabChip Kit (Agilent Technolo-
gies, Palo Alto, CA, USA). All samples used had discernable
18S and 28S ribosomal peaks. First-strand cDNA was synthe-
sized from approximately 1.5 µg total RNA using 500 ng
Oligo(dT)12–18 and Superscript III reverse transcriptase (1st
Strand Kit; Invitrogen, Carlsbad, CA, USA). The reaction was
held at 42°C for 50 minutes followed by a 15-minute step at
70°C. The cDNA was washed on a QIAquick PCR purification
column and was stored at -80°C in 25 mM Tris, 1 mM ethylen-
ediamine tetraacetic acid at a concentration of 5 ng/µl (con-
centration estimated from the starting RNA concentration
used in the reverse transcription).Available online http://breast-cancer-research.com/content/8/2/R23
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Primer design
Genbank sequences were downloaded from Evidence viewer
(NCBI website) into the Lightcycler Probe Design Software
(Roche Applied Science, Indianapolis, IN, USA). All primer
sets were designed to have a Tm of approximately 60°C, to
have a GC content of approximately 50%, and to generate a
PCR amplicon <200 bps. Finally, BLAT and BLAST searches
were performed on primer pair sequences using the UCSC
Genome Bioinformatics database and the NCBI database to
check for uniqueness. Primer sets and identifiers are provided
in Additional file 2 (Supplemental Table 2).
Real-time PCR
For PCR each 20 µl reaction included 1 × PCR buffer with 3
mM MgCl2 (Idaho Technology Inc., Salt Lake City, UT, USA),
0.2 mM each of dATP, dCTP, and dGTP, 0.1 mM dTTP, 0.3
mM dUTP (Roche Applied Science), 10 ng cDNA and 1 U
Platinum Taq (Invitrogen). The dsDNA dye SYBR Green I
(Molecular Probes, Eugene, OR, USA) was used for all quan-
tification (1/50,000 final). PCR amplifications were performed
on the Lightcycler software using an initial denaturation step
(94°C, 90 seconds) followed by 50 cycles: denaturation
(94°C, 3 seconds), annealing (58°C, 5 seconds with 20°C/s
transition), and extension (72°C, 6 seconds with 2°C/sec tran-
sition). Fluorescence (530 nm) from the dsDNA dye SYBR
Green I was acquired for each cycle after the extension step.
The specificity of the PCR was determined by postamplifica-
tion melting curve analysis. Reactions were automatically
cooled to 60°C at a rate of 3°C/s and slowly heated at 0.1°C/
s to 95°C while continuously monitoring the fluorescence.
Relative quantification by real-time qRT-PCR
Quantification was performed using the LightCycler 4.0 soft-
ware. The crossing threshold for each reaction was deter-
mined using the second-derivative maximum method [15,16].
The relative copy number was calculated using an external cal-
ibration curve to correct for PCR efficiency and a within-run
calibrator to correct for the variability between runs. The cali-
brator is made from four equal parts of RNA from three cell
lines (MCF7, SKBR3, and ME16C) and Universal Human Ref-
erence RNA (catalogue number #740000; Stratagene, La
Jolla, CA, USA).
Differences in cDNA input were corrected by dividing the tar-
get copy number by the arithmetic mean of the copy number
for three housekeeper genes (MRPL19, PSMC4, and PUM1)
[17]. After adjusting copy numbers to the reference sample
(calibrator) in LCS4, relative copy numbers were imported into
a relational database where the data were normalized to the
housekeeper genes and were log2-transformed for further
analyses.
Hierarchical clustering was carried out in Cluster analysis
using Spearman correlation, median centering by gene and
array, and average linkage association [18]. The clustering
was visualized using Treeview. The real-time qRT-PCR relative
copy number data for all genes (53 classifier genes and three
housekeeper genes) can be found in Additional file 2 (Supple-
mental Table 3).
Histopathology/immunohistochemistry
Histological assessment of grade was performed for the inva-
sive ductal adenocarcinomas using the Scarff-Bloom-Richard-
son system. Nuclear grading was determined for tumors in
which tubular differentiation could not be assessed (for exam-
ple, invasive lobular carcinomas). Samples were scored for
protein expression at the time of diagnosis and using standard
operating procedures established at each institution. Greater
than 20% positive staining nuclei was considered positive for
the ER and the progesterone receptor. Staining and scoring
criteria for HER2 were carried out according to the Her-
cepTest (Dako, Carpinteria, CA, USA).
Microarray experiments
The 126 samples used for qRT-PCR were also analyzed by
DNA microarray (Agilent Human A1, Agilent Human A2, and
custom oligonucleotide). Labeling and hybridization of RNA
for microarray analysis were performed using the Agilent low
RNA input linear amplification kit, but with one-half of the rec-
ommended reagent volumes and using a Qiagen PCR purifi-
cation kit to clean up the cRNA. Each sample was assayed
versus a common reference sample that was a mixture of
Human Universal Reference total RNA (Stratagene, La Jolla,
CA, USA) enriched with equal amounts of RNA from the
MCF7 and ME16C cell lines. Microarray hybridizations were
carried out on Agilent Human oligonucleotide microarrays
using 2 µg Cy3-labeled 'reference' sample and 2 µg Cy5-
labeled 'experimental' sample. Hybridizations were carried out
using the Agilent hybridization kit and a Robbins Scientific
'22k chamber' hybridization oven (Robbins Scientific, Sunny-
vale, CA, USA). The arrays were incubated overnight, washed
once in 2 × SSC and 0.0005% Triton X-102 (10 minutes),
washed twice in 0.1 × SSC (5 minutes), and were then
immersed into Agilent Stabilization and Drying solution for 20
seconds.
All microarrays were scanned using an Axon Scanner 4000A
(Axon Instruments, Inc, Foster City, CA, USA). The image files
were analyzed with GenePix Pro 4.1 (Axon Instruments) and
were uploaded into the UNC Microarray Database at the Uni-
versity of North Carolina at Chapel Hill, where a lowest normal-
ization procedure was performed to adjust the Cy3 and Cy5
channels [19]. All primary microarray data associated with this
study are available at the UNC Microarray Database and have
been deposited in the GEO under accession number
GSE2607.
Selecting genes for real-time qRT-PCR
We developed a real-time qRT-PCR assay using 53 genes
that were selected due to their importance in making 'intrinsic'Breast Cancer Research    Vol 8 No 2    Perreard et al.
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subtype distinctions and/or their association with cell prolifer-
ation (see Additional file 2, Supplemental Table 2). The statis-
tical selection of 'intrinsic' genes involved using 45 before-
therapy and after-therapy samples derived from the data set
presented in Sorlie and colleagues (see Additional file 2, Sup-
plemental Table 4 for the list of 45 pairs) [5]. The two-color
DNA microarray data were downloaded from the Internet and
the R/G ratio (experimental/reference) for each spot was nor-
malized and log2-transformed. Missing values were imputed
using the k-NN imputation algorithm described by Troyan-
skaya and colleagues [20].
Using an 'intrinsic' analysis [3] we identified 550 microarray
elements/spots from the data set presented by Sorlie and col-
leagues [5]. We then applied the 'intrinsic' genes to identifying
molecular subtypes within a completely independent data set
of early-stage breast cancers [7]. Common elements between
the data sets were found after translating the gene annotation
from each data set to UniGene Cluster IDs using the
SOURCE database [21]. Following the algorithm outlined by
Tibshirani and colleagues [22,23], we hierarchical clustered
the 97 samples from van 't Veer and colleagues' study [7]
using a common set of 350 genes and assigned intrinsic sub-
types (Luminal, HER2+/ER-, Basal-like, or Normal-like) based
on the sample-associated dendrogram. Finally, we identified
genes that optimally distinguished the four subtype classes
using a version of the gene selection method first described by
Dudoit and Fridlyand [24], where the best class distinguishers
are identified according to the ratio of between-group to
within-group sums of squares. After scoring genes in this man-
ner, 10-fold cross-validation was performed with a nearest
centroid classifier, resulting in a list of 41 genes that gave the
highest prediction accuracy when compared with the entire
set of 350 genes.
We successfully developed qRT-PCR assays for 37 out of the
41 genes identified from the 'intrinsic' analysis (minimal intrin-
sic list). The genes PGR and EGFR were also included in the
qRT-PCR assay, despite not being statistically selected in the
'intrinsic' analysis, because of their value in predicting therapy
response and their strong association with ER-positive and
ER-negative tumors. Finally, we tested 14 proliferation genes
because of their importance in prognosis.
Cluster robustness
The stability of our hierarchical clustering classifications was
tested using a k-means algorithm implemented in Cluster 3.0
and using Consensus Cluster [25] implemented in GenePat-
tern. For the k-means we ran 1,000 trials (K = 4 and K = 5)
and used the Euclidean distance as the similarity metric. Con-
sensus clustering was also performed for 1,000 runs using a
'subsampling' of 0.8, so that 20% of the samples were left out
of each run.
Combining microarray and qRT-PCR datasets
We used distance-weighted discrimination (DWD) to identify
and correct systematic biases across the microarray and qRT-
PCR datasets [26]. Prior to DWD, we normalized each data-
set by setting the mean to 0 and the variance to 1. After per-
forming DWD, genes in common between the datasets were
clustered using Spearman correlation and average linkage
association.
Receiver operator curves
In order to determine agreement between protein expression
(immunohistochemistry (IHC)) and gene expression (qRT-
PCR), a cutoff value for the relative gene copy number was
selected by minimizing the sum of the observed false-positive
and false-negative errors; that is, minimizing the estimated
overall error rate under equal priors for the presence/absence
of the protein. The sensitivity and specificity of the resulting
classification rule were estimated via bootstrap adjustment for
optimism [27].
Survival analyses
Survival curves were estimated by the Kaplan-Meier method
and compared via a log-rank or stratified log-rank test as
appropriate. The standard clinical pathological parameters of
age (years), node status (positive versus negative), tumor size
(cm, a continuous variable), grade (1–3, a continuous covari-
ate), and ER status (positive versus negative) were tested for
differences in relapse-free survival (RFS) and overall survival
using the Cox proportional hazards regression model. Pair-
wise log-rank tests were used to test for equality of the hazard
functions among the intrinsic classes. Cox regression was
used to determine predictors of survival from continuous
expression data. All statistical analyses were performed using
the R statistical software package (R Foundation for Statistical
Computing Vienna, Austria).
Results and discussion
Recapitulating microarray-based breast cancer 
classifications using qRT-PCR
Two major challenges in using genomics for breast cancer
diagnostics are the ability to find robust classifications that
maintain prognostic significance across different patient pop-
ulations, and the ability to effectively translate those classifica-
tions into the clinical laboratory. Microarray studies on breast
cancer have shown that particular signatures, such as those
for intrinsic subtype classification and proliferation, are con-
sistently identified and are prognostic across different data
sets [3-5,7,8,14,28]. In order to determine whether the 'intrin-
sic' classifications found by microarray analysis could be gen-
erated from real-time qRT-PCR data, we prospectively
compared the two platforms by profiling 126 different breast
tissue samples (117 invasive, five normal, one fibroadenoma,
and three cell lines) with Agilent microarrays (20,000 ele-
ments) and a real-time qRT-PCR assay. The qRT-PCR assay
was comprised of 53 genes that were selected to optimallyAvailable online http://breast-cancer-research.com/content/8/2/R23
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identify the four main breast tumor intrinsic subtypes [3,4], and
to create an objective gene expression predictor for cell prolif-
eration and outcome [12,29,30].
A major objection to using hierarchical clustering for defining
tumor subtypes is that the algorithms are designed for associ-
ating and visualizing gene expression patterns, and are not
necessarily designed for sample classification. We therefore
tested the 'robustness' of the hierarchical clustering classifica-
tions using a k-means method and consensus clustering [25];
both methods found that there were at least four stable clus-
ters.
There were 402 genes in common between our current micro-
array data set and the 550 intrinsic genes initially identified
using the 45 paired samples taken from Sorlie and colleagues
[5]. Two-way hierarchical clustering of the same 126 samples
using either microarray data for the 402 'intrinsic' genes (Addi-
tional file 1, Supplemental Figure 1) or qRT-PCR data for the
minimal 37 'intrinsic' genes (Figure 1) showed 93% concord-
ance in classification. The samples were grouped into Luminal,
HER2+/ER-, Normal-like, and Basal-like subtypes by both
platforms.
In the qRT-PCR classification, 49 out of 55 (89%) Luminal
tumors with available IHC data were scored positive for ER.
Figure 1
Two-way hierarchical clustering of real-time quantitative reverse-transcription (qRT)-PCR data Two-way hierarchical clustering of real-time quantitative reverse-transcription (qRT)-PCR data. (a) The sample-associated dendrogram groups the 
126 breast samples profiled by qRT-PCR into the same classes seen by microarray analysis. Samples are grouped into Luminal (blue), HER2+/ER- 
(pink), Normal-like (green), and Basal-like (red) subtypes. The expression level for each gene is shown relative to the median expression of that gene 
across all the samples, with high expression represented by red and low expression represented by green. Genes with median expression are black 
and missing values are gray. (b) A minimal set of 37 'intrinsic' genes was used to classify tumors into their primary 'intrinsic' subtypes. The 'intrinsic' 
gene set was supplemented using (c) PgR and EGFR, and (d) proliferation genes. The genes in (c) and (d) were clustered separately in order to 
determine agreement between the minimal 37 qRT-PCR 'intrinsic' set and the larger 402 microarray 'intrinsic' set (see Additional file 1, Supplemen-
tal Figure 1). Overall, 114/123 (93%) primary breast samples were classified the same between microarray and qRT-PCR.Breast Cancer Research    Vol 8 No 2    Perreard et al.
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Conversely, 46 out of 54 (85%) tumors classified as HER2+/
ER- or Basal-like were ER-negative by IHC. A 37-gene qRT-
PCR assay using a minimal intrinsic list can therefore accu-
rately identify intrinsic subtypes and make classifications that
agree with the ER status.
Comparing real-time qRT-PCR with 
immunohistochemistry
Current molecular classifications in surgical pathology are
made by evaluating single markers rather than sets of markers.
We therefore assessed single qRT-PCR markers for their sen-
sitivity/specificity in determining IHC status (Additional file 1,
Supplemental Figure 2) [31]. This was done for similar mark-
ers (for example, ESR1 gene expression compared with ER
protein status) and for surrogate markers (for example, GATA3
gene expression compared with ER protein status). We found
that the gene expression of ESR1 alone had 87% sensitivity
and 90% specificity for predicting the ER status by IHC. The
gene with the highest correlation in expression to ESR1 was
GATA3 (0.79), and GATA3 alone showed 90% sensitivity and
81% specificity. In addition, gene expression of PgR corre-
lated well with the progesterone receptor IHC status (sensitiv-
ity = 89%, specificity = 82%). There was high correlation in
expression between HER2/ERBB2 and GRB7 (0.91), which
are physically located near one another on chromosome
17q12 and are commonly overexpressed and DNA-amplified
together. Both ERBB2 (sensitivity = 55%, specificity = 87%)
and GRB7 (sensitivity = 40%, specificity = 96%) had low sen-
sitivity but high specificity in predicting the HER2 status by
IHC. It is not surprising that there was poor agreement
between ERBB2 gene expression and HER2 scoring since
IHC is known to overestimate HER2 status when compared to
fluorescence in-situ hybridization [32].
Proliferation and grade
Proliferation genes have a high correlation with grade and
have been shown to be a major determinant of outcome in
breast cancer, especially in predicting recurrence in ER-posi-
tive tumors and in women with early-stage disease
[7,8,28,33,34]. For instance, proliferation is a predominant
component of both the Oncotype Dx test (five out of 16 genes
are proliferation markers) [33] and the MammaPrint® microar-
ray assay based on the 70-gene prognosis signature [7]. Sev-
eral of the cell cycle genes identified (STK6, BUB1, and
BIRC5) in those studies were also strong predictors of recur-
rence in this study and were part of our 14-gene proliferation
signature.
Table 1
Correlating proliferation genes with relapse-free survival (RFS) and the grade using the quantitative reverse-transcription PCR 
assay
Gene RFS-gene Grade-gene
All samples Luminal only All samples
adjusted for grade
All samples
adjusted for stage
All samples
adjusted for stage and 
grade
Spearman 
correlation
P value
BIRC5 0.136 0.0679 0.493 0.146 0.348 0.349 0.000156
BUB1 0.00247 0.0658 0.0178 0.00872 0.0258 0.45 6.84 × 10-7
CENPF 0.0204 0.0173 0.149 0.0934 0.295 0.469 2.00 × 10-7
CKS2 0.34 0.621 0.961 0.125 0.313 0.364 7.57 × 10-5
DUFD1 0.0525 0.0411 0.261 0.188 0.417 0.406 8.93 × 10-6
GTPBP4 0.000813 0.0751 0.00636 0.00177 0.00587 0.258 0.00598
HSPA14 0.0527 0.1 0.219 0.00491 0.0132 0.264 0.00467
MK167 0.101 0.0591 0.297 0.119 0.255 0.354 0.000121
MYBL2 0.00229 0.00246 0.0123 0.0318 0.0777 0.409 7.48 × 10-6
NEK2 0.0654 0.436 0.259 0.155 0.346 0.384 2.89 × 10-5
PCNA 0.155 0.166 0.179 0.182 0.152 0.151 0.109
STK6 0.000707 0.0485 0.00602 0.00816 0.0204 0.427 2.67 × 10-6
TOP2A 0.0347 0.291 0.142 0.0871 0.198 0.325 0.000451
TTK 0.00688 0.0651 0.0571 0.0299 0.11 0.4 1.26 × 10-5
Meta-gene 0.00321 0.0185 0.0252 0.0102 0.0301 0.456 4.77 × 10-7Available online http://breast-cancer-research.com/content/8/2/R23
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Analysis of the real-time qRT-PCR data from our 14 selected
'proliferation' genes (Figure 1d) showed that Luminal tumors
have relatively low replication activity compared with HER2+/
ER- and Basal-like tumors. As expected, the Normal-like sam-
ples showed the lowest expression of the 'proliferation' genes.
When correlating (Spearman correlation) the gene expression
of all 53 qRT-PCR genes with grade, we found that the top
genes with a positive correlation (for instance, high expression
correlates with high grade) were the proliferation genes (Table
1). Since the significance of single markers may change
depending on the cohort studied, we also created a prolifera-
tion meta-gene (log2 average of all 14 proliferation genes) as a
potentially more robust measure of grade. The proliferation
meta-gene was more highly correlated with grade (rs = 0.46)
than any other single marker, except CENPF. Genes within the
ER cluster (ESR1, GATA3, and XBP1) all had significant neg-
ative correlations with grade (Additional file 2, Supplemental
Table 5).
Analysis of the proliferation cluster by gene ontology reveals
that these coordinately expressed genes have diverse but
complementary functions important for progression through
the cell cycle, such as DNA replication (PCNA), chromosome
segregation (TOP2A and STK6), and control of cell-cycle
checkpoints (BUB1, MYBL2, and TTK). Although most of the
proliferation genes are overexpressed in high-grade tumors
regardless of their ER status, we found some genes (for exam-
ple, NEK2A) that are 'good' proliferation markers for ER-nega-
tive tumors but not for ER-positive tumors. Genes functioning
in cell polarity and adhesion were not represented in the pro-
liferation genes, which is notable given that differentiation is an
important aspect of histological grade. It is possible that genes
important for tubule differentiation just do not cluster with cell-
cycle-regulated genes or that these functions have yet to be
revealed for genes in the proliferation cluster.
Using qRT-PCR assay for predicting survival
Outcome analyses for the intrinsic subtypes showed that
patients with Luminal tumors showed significantly better out-
comes for RFS and overall survival compared with HER2+/
ER- and Basal-like tumors (Additional file 1, Supplemental Fig-
ure 3). There was no difference in outcome between patients
with HER2+/ER- and Basal-like tumors, with both groups
doing poorly. In addition to determining the prognostic value of
the biological 'intrinsic' subtypes, we also correlated individual
'intrinsic' classifiers (Additional file 2, Supplemental Table 5)
and proliferation genes (Table 1) to the RFS and grade. We
found that the proliferation meta-gene has significant predic-
tive value for RFS (P = 0.003), even after adjusting for other
important determinants of survival (Table 1 and Figure 2).
Since lobular cancers can only be graded on nuclear contours
and not on tubule differentiation, we also performed our anal-
yses using ductal carcinomas only and found that proliferation
was still a better predictor than grade (P = 0.022 versus P =
0.083). It should be noted that the proliferation signature was
not evaluated in the Normal-like breast group because this
group included control samples and few cancer samples.
Because the intrinsic subtypes (and ER status) capture much
of the biology that explains variations in outcome among
breast cancer patients, we tested whether the proliferation
meta-gene added prognostic value to these classifications.
When we separated tumors by intrinsic subtype (and ER sta-
tus), and then stratified by the proliferation meta-gene, we
found that proliferation only added prognostic information in
the Luminal (and ER-positive) subtype of tumors (Figure 3).
Women that had Luminal tumors with high proliferation were
at a 19-fold increased risk of relapse compared with women
that had Luminal tumors with low proliferation. Similarly, ER-
positive tumors with high proliferation conferred a 13-fold rel-
ative risk of relapse.
Finally, we included the genomic classifiers (intrinsic subtype
and proliferation) in multivariate survival analyses with stand-
ard clinical pathological information (Additional file 2, Supple-
mental Tables 6–9). Three multivariate models were applied to
evaluate the contribution from standard clinical parameters
alone (Model 1), from standard parameters plus genomic pro-
liferation (Model 2), and from standard parameters plus prolif-
eration and the intrinsic subtype (Model 3). This was
performed for RFS (Additional file 2, Supplemental Tables 6
and 8) and for overall survival (Additional file 2, Supplemental
Tables 7 and 9). The cohort analyzed by qRT-PCR showed
that, without the addition of genomic classifiers, the top pre-
Figure 2
Grade and proliferation as predictors of relapse-free survival Grade and proliferation as predictors of relapse-free survival. A Cox 
regression model was used to determine probability of relapse over 
time. Kaplan-Meier curves show the time to event given different grades 
and levels of proliferation. The grade was scored as low (green), 
medium (red) or high (blue). The proliferation score was based on con-
tinuous expression data, and is shown as tertiles that correspond to low 
(green), medium (red), and high (blue) levels of expression. The prolifer-
ation meta-gene (log2 average of the 14 proliferation genes) showed 
significant value in predicting relapse, even after correcting for other 
clinical parameters important for survival (Table 1). Furthermore, when 
we include both the grade and proliferation in a model for relapse-free 
survival, we find that the proliferation meta-gene is the better predictor 
(grade, P = 0.51; proliferation index, P = 0.047).Breast Cancer Research    Vol 8 No 2    Perreard et al.
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dictors for RFS were the tumor size, the node status, and the
ER status. The proliferation meta-gene was a significant and
independent predictor of survival in the multivariate analysis.
The Luminal (ER-positive) versus Basal-like (ER-negative) dis-
tinction was significant for overall outcome in the multivariate
analysis, even in the presence of standard ER status by IHC
(Additional file 2, Supplemental Table 7).
Testing the proliferation meta-gene for relapse in early-
stage breast cancers
In order to further validate our observations and to determine
whether our proliferation meta-gene was simply identifying the
Luminal B subtype of tumors, previously described as having
high proliferation and poor outcome [4], we applied the prolif-
eration meta-gene to a large microarray dataset containing
337 patients with long-term follow-up and containing a Lumi-
nal B group. This microarray data set is the combined and non-
redundant sample sets presented in van 't Veer and
colleagues [7] and in Chang and colleagues [14], and repre-
sents a set of breast cancer patients from The Netherlands
Cancer Institute (NKI dataset). Each sample was assigned an
'intrinsic subtype' using five subtype centroids (Luminal A,
Luminal B, Basal-like, HER2+/ER-, and Normal-like), as
described earlier.
By applying the proliferation meta-gene to these subtypes, we
show that proliferation only added prognostic information for
RFS in the Luminal A subtype (Figure 4). The proliferation
meta-gene was also prognostic when samples were classified
more generally into 'Luminal' (Luminal A and Luminal B com-
bined) versus 'HER2/Basal' (Additional file 1, Supplemental
Figure 4), or into ER-positive versus ER-negative as clinically
defined by IHC (Additional file 1, Supplemental Figure 5). It
should be noted that the proliferation signature fails to further
stratify ER-negative tumors (or Basal-like and HER2+/ER-
tumors) because these 'groups' uniformly have high prolifera-
tion. Multivariate analyses of the NKI dataset showed that the
Figure 3
Intrinsic subtype stratified by the proliferation index Intrinsic subtype stratified by the proliferation index. Tumors were given 
an 'intrinsic' subtype assignment based on the minimal 37-gene quanti-
tative reverse-transcription-PCR classifier (Figure 1b). Patients were 
classified as having Luminal (estrogen receptor (ER)-positive) or HER2/
Basal (ER-negative) subtypes. In order to have groups of similar size 
and because the subtypes largely follow ER status, tumors in the HER2 
and Basal-like groups (both ER-negative) were combined. Continuous 
expression data for the proliferation meta-gene (log2 average of the 14 
selected markers) were used in a Cox regression model to determine 
the probability of relapse over time. Differences in relapse for low 
(green), medium (red), and high (blue) expression are shown as tertiles 
in the Kaplan-Meier plots. Stratification by proliferation added informa-
tion for relapse in the Luminal subtype (P = 0.00039) but not the ER-
negative subtypes (P = 0.74).
Figure 4
Stratification of five 'intrinsic' subtypes by the proliferation meta-gene Stratification of five 'intrinsic' subtypes by the proliferation meta-gene. A large microarray breast cancer data set (337 samples × 16,000 genes) from 
women with early-stage disease was used to confirm the significance of the proliferation meta-gene to further risk-stratify the Luminal tumors. 
Tumors were classified as Basal, HER2+/ER-, Luminal A, Luminal B, and Normal-like. The microarray data for the proliferation meta-gene was then 
used in a Cox regression model to determine probability of relapse in women with the different tumor subtypes. Differences in relapse for low 
(green), medium (red), and high (blue) expression are shown as tertiles in the Kaplan-Meier plots. The Kaplan-Meier curves show that proliferation 
adds significant survival information, beyond that gleaned from the intrinsic subtype, only for patients with Luminal A tumors (P = 0.012).Available online http://breast-cancer-research.com/content/8/2/R23
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grade, the ER status, age, and proliferation were all significant
and independent predictors of survival (Additional file 2, Sup-
plemental Tables 8 and 9).
Co-clustering qRT-PCR and microarray data
In order to determine whether qRT-PCR data and microarray
data could be analyzed together as a single dataset, we used
DWD to combine data for 50 genes across the 126 samples
profiled by both qRT-PCR and microarray analyses (252 sam-
ples in total). Hierarchical clustering of these data show that
98% (124/126) of the paired samples were classified as the
same intrinsic subtype and 83/126 (66%) were clustered
directly adjacent to their corresponding partner (Figure 5).
Microarray and real-time qRT-PCR data can therefore be com-
bined into a seamless data set without sample segregation
based on the platform. Overall, the microarray and qRT-PCR
expression data showed high correlation before (0.76) and
after (0.77) DWD correction.
Conclusion
In this study we have shown that the microarray signatures for
the 'intrinsic' subtype and proliferation are reproducible and
prognostic using a real-time qRT-PCR assay. The biological
classification by real-time qRT-PCR makes the important clini-
cal distinction between ER-positive and ER-negative tumors
and identifies additional subtypes that have prognostic value.
We found that our proliferation meta-gene is a robust predictor
of survival across all breast cancer patients and is particularly
important for prognosis in Luminal A (ER-positive) breast can-
cers, which have a worse outcome than expected when prolif-
eration is high. Work by others also supports the finding that a
genomic signature of proliferation is important for predicting
relapse in breast cancer, especially in ER-positive patients
[28,34].
Combining microarray and qRT-PCR data provides a powerful
system for discovering and then translating genomic markers
into the clinical laboratory. Although these platforms are funda-
Figure 5
Co-clustering of real-time quantitative reverse-transcription (qRT)-PCR and microarray data using 50 genes and 252 samples Co-clustering of real-time quantitative reverse-transcription (qRT)-PCR and microarray data using 50 genes and 252 samples. The relative copy 
number (qRT-PCR) and R/G ratio (microarray) for each gene was log2-transformed and combined into a single dataset using distance-weighted dis-
crimination. Two-way hierarchical clustering was performed on the combined dataset using Spearman correlation and average linkage. (a) The sam-
ple-associated dendrogram shows the same classes as seen in Figure 1. Samples are classified as Basal-like (red), HER2+/ER- (pink), Luminal 
(blue), and Normal-like (green). The expression level for each gene is shown relative to the median expression of that gene across all the samples, 
with overexpressed genes in red and underexpressed genes in green. Genes with average expression are black. (b) The gene-associated dendro-
gram shows that the Luminal tumors and Basal-like tumors differentially express estrogen-associated genes (cluster 1); as well as basal keratins 
(KRT 5 and KRT 17), inflammatory response genes (CX3CL1 and SLPI), and genes in the Wnt pathway (FZD7) (cluster 3). The main distinguishers 
of the HER2+/ER- group are low expression of genes in cluster 1 and high expression of genes on the 17q12 amplicon (ERBB2 and GRB7) (clus-
ter 4). The proliferation genes (cluster 2) have high expression in the estrogen receptor (ER)-negative tumors (Basal-like and HER2+/ER-) and low 
expression in ER-positive (Luminal) and Normal-like samples.Breast Cancer Research    Vol 8 No 2    Perreard et al.
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mentally different, the quantitative data across the methods
showed a high correlation. Real-time qRT-PCR is attractive for
clinical use because it is fast, reproducible, tissue-sparing,
quantitative, automatable, and can be performed from
archived (formalin-fixed, paraffin-embedded tissue) samples
[35,36]. The benefit of using real-time qRT-PCR for cancer
diagnostics is that new markers can be readily validated and
implemented, making tests expandable and/or tailored to the
individual. For instance, the proliferation meta-gene could be
used within the context of the intrinsic subtypes or used as an
ancillary test in breast cancer and other tumor types where an
objective and quantitative measure of grade is important for
risk stratification. As more prognostic and predictive signa-
tures are discovered from microarray, it should be possible to
build on our current biological classification and develop cus-
tomized assays for each tumor subtype.
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